PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

SOPHiA GENETICS announces poster presentations at ESMO 2024

Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials

SOPHiA GENETICS announces poster presentations at ESMO 2024
2024-09-12
(Press-News.org) Boston, MA and Rolle, Switzerland, September 12, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being held in Barcelona, Spain September 13-17, 2024. The ESMO Congress is a globally influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.

The details of the presentations are as follows:

Title:  Analytical validation of an NGS panel-based ecDNA detection device for use as a clinical trial assay for the POTENTIATE clinical study of the novel CHK1 inhibitor, BBI-355
Poster Session: New Diagnostic Tools, Poster #1198
Date/Time: Sunday, September 15, 2024, 17h20 CEST
Presenting Author: Julien Pontis, Technical Product Manager and Lead Data Scientist, SOPHiA GENETICS

This poster presentation will focus on the analytical validation of a next-generation sequencing (NGS) panel-based extrachromosomal DNA (ecDNA) detection device. This innovative device has been developed as a clinical trial assay for Boundless Bio’s ongoing, first-in-human POTENTIATE Phase 1/2 clinical study of its lead ecDNA-directed therapy (ecDTx), BBI-355.

“ecDNA-enabled cancers have a unique biology, with a growing body of research showing these tumors rapidly evolve and typically fail to respond to targeted therapies, leading to worse patient prognoses, including poor time to progression and overall survival. We have developed and validated a proprietary algorithm to detect ecDNA from the outputs of NGS panels routinely used to detect alterations in patient tumors that can be used to select patients for clinical trials,” said Julien Pontis, Technical Product Manager and Lead Data Scientist at SOPHiA GENETICS.

Title: TRIDENT: Machine learning (ML) multimodal signatures to identify patients that would benefit most from tremelimumab (T) addition to durvalumab (D) + chemotherapy (CT) with data from the POSEIDON trial
Poster Session: NSCLC, Metastatic, Poster #1325
Date/Time: Saturday, September 14, 2024, 12h00 CEST
Presenting Author: Ferdinandos Skoulidis, Department of Thoracic Medical Oncology, University of Texas MD Anderson Cancer Center

This poster will feature the TRIDENT study, which leverages machine learning to develop multimodal signatures that can identify patients who would benefit most from the addition of tremelimumab to the durvalumab and chemotherapy regimen in the context of first-line treatment of stage IV non-small cell lung cancer. Dr. Ferdinandos Skoulidis from the University of Texas MD Anderson Cancer Center will present the findings, which are based on a retrospective multimodal analysis of the POSEIDON Phase 3 trial.

Abstracts for these posters are available on the conference website.

For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on LinkedIn.

 

# # #

 

About SOPHiA GENETICS 
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

 

Media Contact: 
Kelly Katapodis

media@sophiagenetics.com

END


[Attachments] See images for this press release:
SOPHiA GENETICS announces poster presentations at ESMO 2024 SOPHiA GENETICS announces poster presentations at ESMO 2024 2 SOPHiA GENETICS announces poster presentations at ESMO 2024 3

ELSE PRESS RELEASES FROM THIS DATE:

 New fossil fish species scales up evidence of Earth’s evolutionary march

 New fossil fish species scales up evidence of Earth’s evolutionary march
2024-09-12
Access VIDEO, photos and captions here                      Climate change and asteroids are linked with animal origin and extinction – and plate tectonics also seems to play a key evolutionary role, ‘groundbreaking’ new fossil research reveals. The discovery of an exceptionally well preserved ancient primitive Devonian coelacanth fish in remote Western Australia has been linked to a period of heightened tectonic activity, or movement in the Earth’s crust, according ...

Personal carbon footprint of the rich is vastly underestimated by rich and poor alike, study finds

2024-09-12
The personal carbon footprint of the richest people in society is grossly underestimated, both by the rich themselves and by those on middle and lower incomes, no matter which country they come from. At the same time, both the rich and the poor drastically overestimate the carbon footprint of the poorest people. An international group of researchers, led by the Copenhagen Business School, the University of Basel and the University of Cambridge, surveyed 4,000 people from Denmark, India, Nigeria and the United States about inequality in personal carbon footprints – the total amount of greenhouse gases ...

Tumor-induced B cell changes reveal potential biomarker for treatment response in triple negative breast cancer

2024-09-12
HOUSTON – (Sept. 12, 2024) – Researchers at Baylor College of Medicine and collaborating institutions have discovered new insights into tumor-induced B cell changes in blood and bone marrow of triple negative breast cancer patients. The findings, published in Nature Cell Biology, show two distinct patterns of B cell abnormalities that could serve as blood biomarkers for determining likelihood of response to standard-of-care chemotherapy and immunotherapy. “Even with significant advances in immunotherapy, ...

Ehrapy: A new open-source tool for analyzing complex health data

Ehrapy: A new open-source tool for analyzing complex health data
2024-09-12
Ehrapy is intended to fill a critical gap in the analysis of health data, says Lukas Heumos, one of the main developers and a scientist at the Institute of Computational Biology at Helmholtz Munich and the Technical University of Munich (TUM): “Until now, there have been no standardized tools for systematically and efficiently analyzing diverse and complex medical data. We’ve changed that with ehrapy.” The team behind ehrapy comes from biomedical research and has extensive experience in analyzing complex scientific datasets. “The healthcare sector faces similar challenges in data analysis as ...

Ozone pollution reduces tropical forest growth

Ozone pollution reduces tropical forest growth
2024-09-12
Ozone gas is reducing the growth of tropical forests – leaving an estimated 290 million tonnes of carbon uncaptured each year, new research shows. The ozone layer in the stratosphere shields our planet from harmful ultraviolet radiation – and protecting it is one of the major successes of environmental action. But ozone at ground level – formed by the combination of pollutants from human activities in the presence of sunlight – interferes with plants’ ability to absorb carbon dioxide. Ozone is also harmful to human health. The new study, published in ...

Study finds doctors and patients interested in environmental impact of health care decisions

2024-09-12
BOSTON – Concerns about the environmental impact of healthcare decisions rarely enter into conversations between patients and physicians. However, evidence from a new study led by researchers at Dana-Farber Cancer Institute, shows there's broad interest in changing that. In a series of focus groups conducted in different areas of the United States, doctors and patients expressed openness to considering environmental factors when discussing treatment options. The findings, presented in a paper published online today by Nature Climate Change, suggest that educating physicians about the environmental costs of treatment ...

Five key factors predict the response of cancer patients to immunotherapy

2024-09-12
Barcelona, 12 September 2024 – Immunotherapy has transformed cancer treatment in recent years by enabling the immune system to attack tumour cells. However, only 20-40% of patients respond positively to immunotherapy, and these rates vary across different types of cancer. Predicting which patients will respond to immunotherapy and which will not is currently a highly active area of research. Numerous studies conducted so far have focused on the specific characteristics of tumours, their microenvironment, or the patient's immune ...

Trilobite fossils from upstate New York reveal “extra” set of legs

Trilobite fossils from upstate New York reveal “extra” set of legs
2024-09-12
A new study finds that a trilobite species with exceptionally well-preserved fossils from upstate New York has an additional set of legs underneath its head. The research, led by the American Museum of Natural History and Nanjing University in China, suggests that having a fifth pair of head appendages might be more widespread among trilobites than once thought. Published today in the journal Palaeontology, the study helps researchers better understand how trilobite heads are segmented. Trilobites are ...

Big algebras: A dictionary of abstract math

Big algebras: A dictionary of abstract math
2024-09-12
Several fields of mathematics have developed in total isolation, using their own ‘undecipherable’ coded languages. In a new study published in PNAS, Tamás Hausel, professor of mathematics at the Institute of Science and Technology Austria (ISTA), presents “big algebras,” a two-way mathematical ‘dictionary’ between symmetry, algebra, and geometry, that could strengthen the connection between the distant worlds of quantum physics and number theory. Technical Toolkit: Symmetry and commutativity, from esthetics to functionality Symmetry is not just a question of esthetics and equilibrium, but also a highly recurrent feature throughout the domains ...

BMI’s relation to cancer therapy mortality risks not so straightforward

BMI’s relation to cancer therapy mortality risks not so straightforward
2024-09-12
While being overweight increases the risk of developing lifestyle-related diseases, there is a phenomenon known as the obesity paradox where a decreased risk of death has been seen during cancer therapy. However, that paradox might not be the trend for all cancer therapies, an Osaka Metropolitan University team reports in JAMA Network Open, a publication of the American Medical Association. Led by graduate student Mr. Yasutaka Ihara and Professor Ayumi Shintani of the Graduate School of Medicine’s Department of Medical Statistics, ...

LAST 30 PRESS RELEASES:

SwRI-developed instruments will study potential habitability of Jupiter’s moon Europa

Proposed scoring system may enhance equity in organ transplantation, increase transplant rates and improve patient survival

Survivors of childhood brain cancer are more likely to be held back in school

Updating offshore turbine designs to reflect storms’ complexity is key

Hospital strain during the COVID-19 pandemic and outcomes in older racial and ethnic minority adults

Scientists unveils key role of “selfish DNA” in early human development

Bonobos may be more vulnerable than previously thought, suggests genetics study

Scripps Research scientists discover chemical probes for previously “undruggable” cancer target

Giant Magellan telescope begins primary mirror support system testing

Experimental cancer drug eliminates bone metastases caused by breast cancer in lab models

Political candidates who fight climate change stand to benefit in election

Stand up to Cancer announces new grants supporting pioneering research in six cancer types

Researchers awarded $1.3M to help military Veterans battling Acute Myeloid Leukemia

New hub for high-energy astrophysics — CTAO Science Data Management Centre opens at DESY in Zeuthen

JMIR publications CEO and Executive Editor Gunther Eysenbach achieves #1 ranking as most cited researcher in Medical Informatics for fifth consecutive year

ERC grant for groundbreaking wearable health tech

NIH announces winners of prize competition to improve postpartum maternal health and health equity through innovative diagnostics

APS and SPR honor Dr. Cynthia F. Bearer with the 2025 Mary Ellen Avery Neonatal Research Award

Election delays and voter trust

US air pollution monitoring network has gaps in coverage, say researchers

Continuous monitoring of fatigue in factory workers

Farmer ants’ wearable bacteria

Political polarization and trust

Study uncovers how silkworm moth's odor detection may improve robotics

New study links obesity to elevated hypertension risk among young middle eastern women

How ‘vaccinating’ plants could reduce pesticide use and secure global food supplies

Seven new frog species discovered in Madagascar: sounds like something from Star Trek

New temperatures in two thirds of key tropical forest

Fearful memories of others seen in mouse brain

Rangers lead ground-breaking effort to monitor Uganda's lion population in critical stronghold

[Press-News.org] SOPHiA GENETICS announces poster presentations at ESMO 2024
Research presented will include the applications of new diagnostic tools and machine learning multimodal signatures in clinical trials